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Abstract
Introduction: Cortical thickness has been proposed as a biomarker of Alzheimer’s dis-
ease (AD)– related neurodegeneration, but the nature of its relationship with amyloid
beta (A𝛽) deposition and white matter hyperintensity volume (WMHV) in cognitively
normal adults is unclear.
Methods:We investigated the influences of A𝛽 status (negative/positive) and WMHV
on cortical thickness in 408 cognitively normal adults aged 69.2 to 71.9 years who
underwent 18F-Florbetapir positron emission tomography (PET) and structural mag-
netic resonance imaging (MRI). Two previously defined Alzheimer’s disease (AD) cor-
tical signature regions and the major cortical lobes were selected as regions of interest
(ROIs) for cortical thickness.
Results: Higher WMHV, but not A𝛽 status, predicted lower cortical thickness across
all participants, in all ROIs. Conversely, when A𝛽-positive participants were considered
alone, higher WMHV predicted higher cortical thickness in a temporal AD-signature
region.
Discussion: WMHV may differentially influence cortical thickness depending on the
presence or absence of A𝛽 , potentially reflecting different pathological mechanisms.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
c○ 2020 The Authors. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring published byWiley Periodicals, Inc. on behalf of the Alzheimer’s Association.
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1 INTRODUCTION
Cortical thickness has been proposed as a biomarker of neurodegen-
eration across the pathophysiological continuum of Alzheimer’s dis-
ease (AD).1-3 It is vital to understand the pathological factors that may
influence such biomarkers, particularly in asymptomatic individuals,
who represent an increasingly important target population for poten-
tial disease-modifying therapies4 and where objective biomarkers are
likely to play key roles in the interpretation of such therapeutic trials in
the future.5
Although the relationship between amyloid beta (A𝛽)
deposition6-18—one of the earliest hypothesized changes in the
AD-continuum19—and cortical thickness, as well as the relationship
between white matter hyperintensity volume (WMHV)20-24—
largely considered to be a surrogate marker of cerebral small vessel
vasculopathy25—and cortical thickness, have been investigated in
cognitively normal adults in isolation, there has been limited research
looking at the relative influences of A𝛽 deposition and WMHV on
cortical thickness concurrently.
We report a cross-sectional analysis of 408 cognitively normal indi-
viduals (ages 69.2 to 71.9 years) all born inmainlandBritain in the same
week of 1946 who underwent clinical assessment, 18F-Florbetapir
positron emission tomography (PET) and volumetric structural mag-
netic resonance imaging (MRI). The aim of this analysis was to investi-
gate the hypothesis that A𝛽 deposition andWMHV predict lower cor-
tical thickness and to investigate potential interactions in their effects.
2 METHODS
2.1 Participants
Data were analyzed from individuals who participated in a neuro-
science sub-study (Insight 46) of the MRC National Survey of Health
and Development (NSHD), a birth cohort study originally compris-
ing 5362 individuals born in mainland Britain in 1 week of 1946.26
A total of 502 NSHD members were recruited to Insight 46 and
underwent detailed clinical and neuropsychological assessment, MRI,
and 18F-florbetapir PET imaging.27,28 Ethical approval was granted by
the National Research Ethics Service Committee London (reference
14/LO/1173) and participants provided written informed consent.
Participants were assessed for a history of cognitive impairment,
and major neurological or psychiatric illness. If a participant reported
memory or cognitive difficulties they perceived as more than oth-
ers the same age, or if they felt they would seek medical attention
regarding cognitive difficulties, they were defined as having subjective
memory complaints. A collateral cognitive history was acquired using
the an eight-item informant interview validated to differentiate aging
and dementia (AD8) questionnaire29 and informant cognitive concern
was defined as an AD8 score ≥2. Participants were defined as having
mild cognitive impairment (MCI) if there was evidence of subjective
cognitive concerns from the participant or the informant AND objec-
tive evidence of an amnestic (logical memory delayed recall score≥1.5
standard deviations [SD] below the mean) or non-amnestic cognitive
deficit (digit-symbol substitution score≥1.5 standard deviations below
the mean), AND there was no evidence of dementia. Logical memory
delayed recall and digit-symbol substitutionwere selected for this pur-
pose, as they were both normally distributed.
Cognitive testing in Insight 4627,28 included: the Mini-Mental State
Examination (MMSE), the digit-symbol substitution test from the
Wechsler Adult Intelligence Scale-Revised, logical memory delayed
recall from the Wechsler Memory Scale-Revised, matrix reasoning
from the Wechsler Abbreviated Scale of Intelligence, and the 12-item
Face-Name test. Childhood cognitive function and educational attain-
ment data were also available to characterize the sample. Childhood
cognitive function was measured at age 8 (or age 11 or 15, if this
was missing) as the sum of scores of four tests of verbal and non-
verbal ability standardized into a z-score.30 Educational attainment
was dichotomized into those with advanced (eg, "A level") or higher
(eg, university) qualifications, versus those below this level.31 APOE
genotype (𝜀4 carrier or non-carrier), diabetes (based on a hemoglobin
A1c (HbA1c) >6.5% at 65 years old, or prescription of diabetic med-
ication at current assessment), hypertension (based on prescription
of anti-hypertensive agent or a blood pressure >140/90 mm Hg at
current assessment), hypercholesterolemia (based on prescription of
a cholesterol-lowering agent) and smoking (smoked or never smoked
based on questionnaire data aged 68 years) were also binarized to
characterize the sample.
Exclusions from the analysis were the following: failure to complete
the PET/MRI scan (n = 31); PET acquisition failure (n = 8); WMHV
segmentation quality control failure (n = 4); cortical thickness imaging
quality control failure (n=3); and participantswith evidence of demen-
tia,MCI, ormajor neurological (including clinical history or radiological
evidence of a cortical stroke) or psychiatric disorder (n= 48).
2.2 Florbetapir-PET
Concurrent acquisition of PET and MRI was performed on the same
Siemens Biograph mMR 3 Tesla PET/MRI scanner. A𝛽 burden was
assessed during a 10-minute period ≈50 minutes after injection of
≈370 MBq of 18F-florbetapir. PET data were processed using an
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automated in-house processing pipeline including pseudo-CT (com-
puted tomography) attenuation correction.32 A global standard uptake
value ratio (SUVR) was calculated from a cortical gray matter compos-
ite (composed of the lateral and medial frontal, anterior and posterior
cingulate, lateral parietal, and lateral temporal regions) using aneroded
subcortical white matter reference region. Positive or negative A𝛽 sta-
tus was determined using a Gaussian mixture model applied to SUVR
values, taking the 99th percentile of the A𝛽-negative Gaussian as the
cut-point (0.6104).28
2.3 StructuralMRI
MRI sequences pertaining to this analysis included volumet-
ric T1-weighted magnetization prepared rapid gradient echo
(MPRAGE) images (voxel size 1.1 × 1.1 × 1.1 mm3 isotropic; inver-
sion time/repetition time (TI/TR) = 870/2000 ms, total time =
5 minutes 6 seconds); volumetric T2-weighted sampling perfection
with application optimized contrasts using different flip angle evolu-
tion (SPACE) images (voxel size 1.1 × 1.1 × 1.1 mm3 isotropic; echo
time (TE)/TR = 409/3200 ms, total time = 4 minutes 43 seconds);
and volumetric fluid-attenuated inversion recovery (FLAIR) inversion
recovery sampling perfection with application optimized contrasts
using different flip angle evolution (IR-SPACE) images (voxel size
1.1 × 1.1 × 1.1 mm3 isotropic; TE/TI/TR = 402/1800/5000 ms, total
time = 6 minutes 27 seconds). All MRI data were pre-processed for
gradwarp and image inhomogeneity.27
Cortical thickness estimation was performed using FreeSurfer ver-
sion 6.0.33,34 Two modifications to the standard automated pipeline
were performed: a locally generated manually edited brain mask
was used to improve skull stripping accuracy; and both T1-weighted
and T2-weighted images were used as inputs to improve segmen-
tation accuracy (https://surfer.nmr.mgh.harvard.edu/fswiki/recon-all#
UsingT2orFLAIRdatatoimprovepialsurfaces).
Cortical thickness regions of interest (ROIs) included surface area–
weighted averages of two previously proposed composite signatures
of AD cortical thinning (Figure 1): one based on work by Jack and
colleagues1 comprising select temporal cortex regions (entorhinal,
fusiform, inferior, and middle temporal—“ADsigMayo”), and one based
on work by Dickerson and colleagues,2,3,35,36 which includes select
frontal, temporal and parietal regions (entorhinal cortex, parahip-
pocampus, inferior parietal lobe, pars opercularis, pars orbitalis, pars
triangularis, inferior temporal lobe, temporal pole, precuneus, supra-
marginal gyrus, superior parietal lobe, and superior frontal lobe—
“ADsig Harvard”). In addition, we generated ROIs for surface area–
weighted averages of the four major cortical lobes (frontal, tempo-
ral, parietal, and occipital—https://surfer.nmr.mgh.harvard.edu/fswiki/
corticalParcellation) to assess broad trends across the whole cortex
(see Table 1).
Bayesian Model Selection (BaMoS),25 a validated automated seg-
mentation tool that uses jointly volumetric T1-weighted and FLAIR
MRI data, was used to generate an estimate of WMHV. This gener-
HIGHLIGHTS
• Cortical thickness is a biomarker of neurodegeneration in
Alzheimer’s disease
• In 408 healthy 70-year-olds amyloid beta (A𝛽) positivity
did not predict cortical thickness
• Overall, higher white matter hyperintensity volume pre-
dicted lower cortical thickness
• There was evidence this relationship differed in the con-
text of A𝛽 deposition
RESEARCH INCONTEXT
Systematic review: The authors searched PubMed for arti-
cles assessing the relationship between cortical thickness
and both amyloid beta (A𝛽) deposition, and white matter
hyperintensity volume (WMHV). Although, cortical thick-
ness is a widely applied biomarker of neurodegeneration
across the pathophysiological continuum of Alzheimer’s
disease (AD), there has been limited research looking at the
relative influences of A𝛽 deposition and WMHV on cortical
thickness concurrently.
Interpretation:We found thatWMHV is a stronger predictor
of cortical thickness thanA𝛽 deposition in cognitively normal
70-year-olds. Furthermore, we found that WMHV may be
differentially associated with cortical thickness according to
the extent of A𝛽 deposition. This has implications for the use
of cortical thickness as a biomarker of neurodegeneration in
the preclinical phase of AD and suggests that WMHV may
reflect different pathological mechanisms in the presence of
A𝛽 accumulation.
ates a global value that includes subcortical gray matter but excludes
infratentorial regions;moredetail of howBaMoSwas applied to Insight
46 data has been described in detail elsewhere.37
2.4 Statistical approach
Wilcoxon rank-sum tests, or where the outcome was normally dis-
tributed, two-sample t tests were used to compare continuous clinical
and cognitive characteristics between A𝛽-positive and A𝛽-negative
groups. Logistic regression models were used to compare categorical
variables between A𝛽-positive and A𝛽-negative groups. Spearman
correlation coefficients were used to assess unadjusted relationships
between WMHV and continuous variables. Wilcoxon rank-sum tests
were used to test associations between WMHV and categorical
variables.
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F IGURE 1 AD cortical signature composites used in the analysis.
ADsigMayo (top row), surface area–weightedmean of entorhinal
cortex, fusiform, inferior, andmiddle temporal regions; ADsig Harvard
(bottom row), surface area–weightedmean of entorhinal cortex,
parahippocampus, inferior parietal lobe, pars opercularis, pars
orbitalis, pars triangularis, inferior temporal, temporal pole,
precuneus, supramarginal gyrus, superior parietal, and superior
frontal regions; AD, Alzheimer’s disease
Linear regression models were used to test the hypothesis that A𝛽
status, and global WMHV independently predicted cortical thickness
in each cortical ROI (dependent variable), adjusting for sex and age
at time of scan. A similar analysis using global SUVR as a continuous
measure of A𝛽 load to predict cortical thickness was also performed
(covariates = WMHV, sex, and age at time of scan). In addition, the
interaction term between A𝛽 status and global WMHV was added to
each model to test the hypothesis that the two interact in terms of
their effect on cortical thickness. In the cortical ROIs where there was
evidence of a significant interaction, linear regression was then used
to test the hypothesis that global WMHV was associated with corti-
cal thickness in each ROI in the A𝛽-negative and A𝛽-positive popula-
tions separately, adjusting for sex and age at time of scan. Q-Q plots
and residual-versus-fitted plots were generated to test the assump-
tions that the outcome variables and their residuals were normally dis-
tributed with constant variance. Robust standard errors were used to
account for non-constant variance. All analyses were performed using
Stata version 14.
3 RESULTS
3.1 Sample characterization
Seventy-four of 408 (18.1%) of cognitively normal individuals were
A𝛽 positive. APOE genotype strongly predicted A𝛽 status, with 𝜀4
carriers being five times more likely to be A𝛽 positive. There were
no statistically significant differences between A𝛽-positive and A𝛽-
negative individuals in the following: age at time of scan, WMHV, sex,
childhood cognitive ability, educational attainment, logical memory,
digit-symbol substitution scores, 12-item Face-Name test score, dia-
betes, hypercholesterolemia, or smoking. Matrix reasoning andMMSE
scoresweremarginally lower in theA𝛽-positive group compared to the
A𝛽-negative group, as reported previously (see Table 2).28
In unadjusted analyses, there was no evidence of an association
at the 5% level between WMHV and sex, childhood cognitive ability,
educational attainment, MMSE, logical memory delayed recall, matrix
reasoning, 12-item Face-Name test score, APOE genotype, diabetes,
hypercholesterolemia, or smoking (Table 2). There was some evidence
of a positive association between greater age at time of scan and
WMHV (P = 0.013), a negative association between digit-symbol sub-
stitution score and WMHV (P = 0.03), and that individuals with a his-
tory of hypertension had higherWMHV (P= 0.004).
3.2 Cortical thickness and A𝜷 deposition
Therewas no evidence that A𝛽 status or SUVRpredicted cortical thick-
ness in any cortical ROI investigated following adjustment for age at
time of scan, sex, and WMHV (Table 3). To explore whether adjust-
ment for WMHV had removed a statistically significant association
between A𝛽 cortical thickness, the same analysis without adjustment
forWMHVwas performed. However, this made nomaterial difference
to the results obtained (data not shown).
3.3 Cortical thickness andWMHV
Across all participants, there was evidence that WMHV predicted
lower cortical thickness in all ROIs investigated independent of A𝛽
deposition, age at time of scan, and sex. In addition, therewas evidence
TABLE 1 Regions from the FreeSurfer Desikan atlas contributing to surface area–weighted averages of major cortical lobe cortical thickness
data
Lobe Regions from the FreeSurfer Desikan atlas—https://surfer.nmr.mgh.harvard.edu/fswiki/corticalParcellation
Frontal Superior frontal, rostral middle frontal, caudal middle frontal, pars opercularis, pars triangularis, pars orbitalis, lateral orbitofrontal,
medial lateral orbitofrontal, precentral, paracentral, frontal pole, rostral anterior cingulate, and caudal anterior cingulate
Temporal Superior temporal, middle temporal, and inferior temporal, banks of the superior temporal sulcus, fusiform, transverse temporal,
entorhinal, temporal pole, and parahippocampal
Parietal Superior parietal, inferior parietal, supramarginal, postcentral, precuneus, posterior cingulate, and isthmus cingulate
Occipital Lateral occipital, lingual, cuneus, and pericalcarine
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TABLE 2 Sample characterization
A𝜷-negative
(n= 334)
A𝜷-positive
(n= 74)
A𝜷-negative vs
A𝜷-positive
Unadjusted association
withWMHV(n= 408)
Age, years, median (IQR) 70.7 (1.2) 70.7 (1.1) P= 0.66a Rho= 0.12; P= 0.013*,b
Male sex, n (%) 166 (49.7%) 40 (54.1%) OR 0.84; P= 0.5c P= 0.17a
Earliest childhood cognitive ability, z-score 0.41 (0.74) 0.44 (0.75) P= 0.74d Rho=−0.05; P= 0.27b
Advanced level of education, n (%) 181 (54.2%) 37 (50%) OR 0.85; P= 0.51c P= 0.86a
MMSE, median (IQR), maximum score= 30 30 (1) 29 (1) P= 0.063a Rho=−0.03; P= 0.52b
Logical memory score, mean (SD), maximum score= 25 11.7 (3.6) 11.3 (3.7) P= 0.33d Rho=−0.05; P= 0.35b
Digit-symbol substitution score, mean (SD), maximum
score= 93
48.8 (10.1) 46.9 (9.7) P= 0.14d Rho=−0.11; P= 0.03*,b
Matrix reasoning, median (IQR), maximum score= 32 26 (4) 25 (4) P= 0.037*,a Rho=−0.04; P= 0.47b
12-Item Face-Name test, median (IQR), maximum
score= 96
66 (28) 68 (27) P= 0.29a Rho= 0.05; P= 0.34b
APOE 𝜀4 carrier, n (%) (missing data: n= 2) 76 (22.9%) 45 (60.8%) OR 5.22; P< 0.0001c P= 0.49a
Hypertension, n (%) (missing data: n= 1) 217 (64.9%) 42 (57.5%) OR 0.73; P= 0.23c P= 0.004*,a
Hypercholesterolemia, n (%) 116 (34.7%) 28 (37.8%) OR 1.14; P= 0.61c P= 0.22a
Diabetes, n (%) (missing data: n= 4) 35 (10.6%) 9 (12.1%) OR 1.17; P= 0.7c P= 0.14a
Ever-smoked, n (%) 216 (64.7%) 46 (62.1%) OR 0.89; P= 0.68c P= 0.32a
WMHV,milliliters, median (IQR) 2.85 (4.84) 3.30 (4.97) P= 0.48a -
Wilcoxon rank-sum tests, or two-sample t tests if the outcome was normally distributed, were used to compare continuous clinical and cognitive charac-
teristics between A𝛽-positive and A𝛽-negative groups. Logistic regression models were used to compare categorical variables between A𝛽-positive and
A𝛽-negative groups. Spearman correlation coefficients were used to assess unadjusted relationships between WMHV and continuous variables. Wilcoxon
rank-sum tests were used to test associations betweenWMHV and categorical variables. IQR, interquartile range; MMSE, Mini-Mental State Examination;
OR, odds ratio;WMHV, whitematter hyperintensity volume (milliliters).
aWilcoxon rank-sum test.
bSpearman rank correlation.
cLogistic regression.
dt test.
* = P< 0.05.
TABLE 3 Association between A𝛽-deposition (binary: positive/negative status, and continuous: SUVR classification) and cortical thickness in
Insight 46
ROIs
A𝜷-negativemean
cortical thickness
(SD), mm
A𝜷-positivemean
cortical thickness
(SD), mm
Mean difference
(95%CI), mm P-value
𝜷-Coefficient
between SUVR and
cortical thickness P-value
Frontal 2.76 (0.09) 2.75 (0.09) −0.01 (−0.03, 0.01) 0.32 −0.10 (−0.24, 0.05) 0.18
Temporal 2.86 (0.09) 2.87 (0.09) 0.00 (−0.02, 0.03) 0.71 −0.03 (−0.15, 0.09) 0.64
Parietal 2.47 (0.08) 2.48 (0.09) 0.01 (−0.01, 0.03) 0.32 −0.02 (−0.15, 0.11) 0.82
Occipital 2.19 (0.09) 2.20 (0.1) 0.01 (−0.02, 0.03) 0.65 −0.07 (−0.22, 0.08) 0.37
ADsigMayo 2.89 (0.09) 2.89 (0.09) 0.01 (−0.02, 0.03) 0.59 −0.05 (−0.18, 0.08) 0.48
ADsig Harvard 2.68 (0.07) 2.69 (0.08) 0.00 (−0.02, 0.02) 0.83 −0.05 (−0.17, 0.08) 0.44
Mean difference calculated following linear regression analysis with robust standard error. 𝛽-Coefficients were adjusted for age at scan, sex, andWMHV.
A𝛽 , amyloid 𝛽; ADsig Mayo, surface area–weighted mean cortical thickness in entorhinal cortex, fusiform, inferior and middle temporal regions; ADsig Har-
vard, surface area–weighted mean cortical thickness in entorhinal cortex, parahippocampus, inferior parietal lobe, pars opercularis, pars orbitalis, pars tri-
angularis, inferior temporal, temporal pole, precuneus, supramarginal gyrus, superior parietal, and superior frontal regions; ROIs, regions of interest; SUVR,
standard uptake value ratio;WMHV, whitematter hyperintensity volume.
of a positive interaction betweenA𝛽 status andWMHV in terms of their
effects on cortical thickness in the temporal lobe andADsigMayoROIs,
and to a lesser extent the frontal lobe (Table 4).
In ROIswhere therewas evidence of an interaction betweenA𝛽 sta-
tus and WMHV, we also stratified participants into A𝛽-negative and
A𝛽-positive groups to test if WMHV differentially influenced cortical
thickness in the two groups. In A𝛽-negative individuals alone therewas
strong evidence of an association between increasing global WMHV
and lower cortical thickness in all ROIs investigated after adjusting for
age at scanning and sex. However, in the A𝛽-positive group, a negative
association betweenWMHVand cortical thicknesswas not clearly evi-
dent, and therewas evidence that higher globalWMHVwas associated
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TABLE 4 Association betweenWMHV and cortical thickness in Insight 46
ROIs
𝜷-Coefficient
betweenWMHVand
cortical thickness† P-value
Interaction term
between A𝜷 status
andWMHV† P-value
Frontal −3.55 (−5.07,−2.03) <0.001* 3.65 (0.66, 6.65) 0.017*
Temporal −3.3 (−4.81,−1.79) <0.001* 5.77 (2.8, 8.72) <0.001*
Parietal −1.24 (−2.41,−0.06) 0.039* −0.29 (−3.56, 2.97) 0.86
Occipital −1.89 (−3.39,−0.39 0.013* 1.91 (−2.63, 6.47) 0.41
ADsigMayo −1.99 (−3.5,−0.47) 0.01* 6.07 (3.11, 9.04) <0.001*
ADsig Harvard −1.51 (−2.59,−0.44) 0.006* 1.17 (−1.56, 3.89) 0.4
𝛽-Coefficients were adjusted for age at scan, sex, and A𝛽 status.
A𝛽 , amyloid 𝛽; ADsig Mayo, surface area–weighted mean cortical thickness in entorhinal cortex, fusiform, inferior, and middle temporal regions; ADsig Har-
vard, surface area–weighted mean cortical thickness in entorhinal cortex, parahippocampus, inferior parietal lobe, pars opercularis, pars orbitalis, pars tri-
angularis, inferior temporal, temporal pole, precuneus, supramarginal gyrus, superior parietal, and superior frontal regions; ROIs, regions of interest; SUVR,
standard uptake value ratio;WMHV, whitematter hyperintensity volume.
*= P< 0.05.
†=mm/ml × 10−3.
TABLE 5 Association betweenWMHV and cortical thickness in Insight 46 following stratification based on A𝛽 status
ROIs
𝜷-Coefficient between
WMHV and cortical
thickness A𝜷-negative,
n= 334† P-value
𝜷-Coefficient
betweenWMHV and
cortical thickness
A𝜷-positive, n= 74† P-value
Frontal −4.21 (−5.89,−2.53) <0.001* −0.56 (−3.2, 2.07) 0.67
Temporal −4.35 (−5.9,−2.8) <0.001* 1.3 (−1.2, 0.39) 0.29
ADsigMayo −3.13 (−4.66,−1.6) <0.001* 2.9 (0.33, 5.47) 0.027*
𝛽-Coefficients were adjusted for age at scan and sex.
A𝛽 , amyloid 𝛽; ADsig Mayo, surface area–weighted mean cortical thickness in entorhinal cortex, fusiform, inferior, and middle temporal regions; ADsig Har-
vard, surface area–weighted mean cortical thickness in entorhinal cortex, parahippocampus, inferior parietal lobe, pars opercularis, pars orbitalis, pars tri-
angularis, inferior temporal, temporal pole, precuneus, supramarginal gyrus, superior parietal, and superior frontal regions; ROIs, regions of interest; SUVR,
standard uptake value ratio;WMHV, whitematter hyperintensity volume.
*= P< 0.05.
† =mm/mL× 10−3.
with increased cortical thickness in the ADsig Mayo ROI (P = 0.027)
(Table 5).
In a post hoc analysis we also explored whether the patterns
observed were related to APOE genotype by adding APOE 𝜀4 car-
rier status as a covariate, as well an interaction term between APOE
𝜀4 carrier status and WMHV, to the statistical models and this made
no material difference to the results obtained. Given the possibility
thatWMHVmay reflect different pathologicalmechanisms in different
contexts, we also explored whether hypertension predicted WMHV
differentially in A𝛽-negative and A𝛽-positive groups using Wilcoxon
rank-sum tests. A𝛽-Negative individuals with a history of hypertension
had higher WMHV (P = 0.0017), whereas there was no evidence of an
association in A𝛽-positive participants (P= 0.84).
4 DISCUSSION
In this study of 408 age-matched cognitively individuals, we found
no evidence, even at a trend level, for cross-sectional associations
between A𝛽 deposition and cortical thickness in any of the ROIs
investigated. Although some studies have shown evidence of asso-
ciations between A𝛽 deposition and cortical thickness in cognitively
normal individuals,7,11-13,35 several studies have also reported null
findings.14-17 Because AD is associated with cortical thinning, the lack
of association in this cohort may reflect the age of the participants
investigated. These participants were just at the beginning of the
eighth decade, and at this age the majority of A𝛽-positive individu-
als are likely to be in a relatively early stage of the pathophysiolog-
ical continuum of AD,38-40 and so potentially many years before the
onset of AD-related neurodegeneration. Many previous studies have
utilized data sets with older age ranges, which increases the probabil-
ity of including participants closer to symptomonset and consequently
with more significant AD-related neurodegeneration. A further impor-
tant considerationwhen evaluating inconsistencies between studies in
the literature is the large array ofmethodological factors that influence
PET-derived quantitative estimates of A𝛽 deposition.41 However, it is
worth noting that the rate of A𝛽 positivity in this cohort was consis-
tent with meta-analyses of A𝛽-PET imaging studies of cognitively nor-
mal individuals,38 which increases confidence in the reliability of the
methodology utilized in this study.
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Although we found no relationship between A𝛽 deposition and
cortical thickness, higher WMHV strongly predicted lower cortical
thickness across all participants. This is consistent with previous
studies, which have provided evidence for cross-sectional associations
between increasing WMHV and gray matter atrophy20-24; this study
confirms and extends these findings, allowing for associations with A𝛽
deposition to be explored.
We found evidence for an interaction between A𝛽 status and
WMHV in terms of their effects on cortical thickness. When A𝛽-
positive participants were considered alone, there was some evidence
that higher WMHV predicted higher cortical thickness in the ADsig
Mayo ROI. Although the statistical effect in A𝛽-positive participants
was relatively weak (P = 0.027), the interaction effect between A𝛽
status and WMHV across all participants was strong (P < 0.001 in
temporal ROIs). Although paradoxical increases in cortical gray matter
structuralmetricswithA𝛽 depositionhavebeen reported in cognitively
normal individuals,8-10,18 to our knowledge, a positive association
between WMHV and cortical thickness has not been reported previ-
ously in individuals with asymptomatic A𝛽 deposition. However, a simi-
lar interaction in the setting of clinically establishedADconsistentwith
our findings, also localized to the temporal lobe, has been reported.42
The mechanism(s) leading to positive associations betweenWMHV
and cortical thickness are unclear. ElevatedWMHVmay reflect patho-
logical processes other than conventional cerebrovascular disease in
the context of AD.43,44 In a large cohort of non-demented older adults,
Graff-Radford et al. found white matter hyperintensities to be corre-
latedwithA𝛽 load,with evidence implicating cerebral amyloid angiopa-
thy rather than small vessel vasculopathy.45 It is notable that in our
study hypertension was strongly related toWMHV in the A𝛽-negative
population, consistent with this being due to small vessel vasculopa-
thy, whereas therewas no evidence of an association in theA𝛽-positive
sample, noting differences in sample size betweenA𝛽-negative andA𝛽-
positive groups. Another possibility for this unexpected relationship is
neuroinflammation. Recent work has demonstrated positive associa-
tions between PET radiotracer uptake of markers of microglial activa-
tion and gray matter volumes in the setting of MCI.46 It is also pos-
sible that this is reflective of a selection effect, whereby those with
a thicker cortex are more likely to be recruited to an intensive neu-
roimaging study and be defined as cognitively normal in the context
of a higher WMHV load and A𝛽 positivity. Longitudinal imaging and
neuropsychology data will be important to further explore the conse-
quence of this observed effect, whereas ultimately large-scale post-
mortemdatawill be vital to investigate further thepathological hetero-
geneity underlying white matter hyperintensities in the context of A𝛽
deposition.
This study has a number of strengths and weaknesses. Because
all subjects were of near identical age—separated only by the ≈2 to
3 years required to complete scanning—the effects of age on any
relationships are limited. We do not have a measure of neurofibrillary
tangle deposition such as tau PET, which is more closely linked to
neurodegeneration and cognitive decline than A𝛽47,48; recent work
has shown that tau PET tracer uptake is strongly correlatedwith lower
cortical thickness and may mediate relationships between A𝛽 and cor-
tical atrophy.49 However, the study by Graff-Radford and colleagues
demonstrated no relationship between increased tau andwhitematter
hyperintensity burden,45 suggesting that it is unlikely to play a role in
the interactions between A𝛽 and WMHV in terms of their effects on
cortical thickness in our data set. We considered A𝛽 and WMHV on a
global scale, and future work looking at regional differences in patho-
logical biomarkers and cortical thickness will be of interest, as will
work looking at relevant whitematter pathways using diffusionMRI.50
Although the broader NSHD is highly representative of individuals
born in mainland Britain in 1946,26 intensive neuroimaging studies
such as Insight 46 are at risk of introducing an element of recruit-
ment bias; we have previously shown that Insight 46 participants are
on average slightly more educated, as well as more likely to being
defined as having a non-manual occupation.51 However, compared to
many other intensive data-rich neuroimaging studies, which rely on
convenience sampling methodology,52 this is likely to remain a fairly
representative samples, noting that all NSHD participants are white,
which is reflective of the British population in 1946, but not the richer
ethnic diversity present in themodern United Kingdom.
In conclusion, we found thatWMHV is a stronger predictor of corti-
cal thickness than A𝛽 deposition in normal 70-year-olds. This, and the
demonstration that WMHV may be differentially associated with cor-
tical thickness according to A𝛽 status, has implications for the use of
cortical thickness as a biomarker of AD-related neurodegeneration in
the preclinical phase and suggests that WMHV may reflect different
pathological mechanisms in the presence of A𝛽 accumulation.
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